Pharmaceutical Preparations · DE · CIK 1802665
Harmony Biosciences develops and commercializes innovative treatments for rare neurological diseases, focusing on sleep/wake disorders and epilepsy
Comparable business profile · signals at a glance
Coverage (30d): 1 reputable article.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
In the 90 days to Jan 26, 2026: 2 sold $2.8M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 26, 2026 | Kapadia SandipCHIEF FINANCIAL OFFICER | Sell | 3,746 | $37.15 | $139K |
| Jan 15, 2026 | Kapadia SandipCHIEF FINANCIAL OFFICER | Sell | 20,961 | $35.92 | $753K |
| Dec 12, 2025 | Dayno Jeffrey M.PRESIDENT, CEO | Sell | 20,000 | $40.11 | $802K |
| Dec 12, 2025 | Dayno Jeffrey M.PRESIDENT, CEO | Sell | 5,933 | $40.11 | $238K |
| Dec 5, 2025 | Kapadia SandipCHIEF FINANCIAL OFFICER | Sell | 20,000 | $39.54 | $791K |
| Nov 21, 2025 | Kapadia SandipCHIEF FINANCIAL OFFICER | Sell | 3,427 | $35.00 | $120K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.